HC Wainwright Issues Positive Forecast for HOWL Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Werewolf Therapeutics from ($0.47) to ($0.41), with full-year earnings projected at ($1.56) per share.
• Wedbush decreased its price target for Werewolf Therapeutics from $8.00 to $6.00 while maintaining an "outperform" rating for the company.
• Hedge funds have been increasing their positions in Werewolf Therapeutics, with significant purchases from firms like D.E. Shaw & Co. and Jane Street Group LLC.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities researchers at HC Wainwright raised their Q3 2025 earnings estimates for shares of Werewolf Therapeutics in a research report issued to clients and investors on Thursday, August 14th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.41) per share for the quarter, up from their previous forecast of ($0.47). The consensus estimate for Werewolf Therapeutics' current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Werewolf Therapeutics' Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($0.80) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at ($1.16) EPS and FY2029 earnings at ($0.70) EPS.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10.

HOWL has been the topic of a number of other research reports. JMP Securities decreased their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating on the stock in a research note on Thursday. Wedbush decreased their price target on shares of Werewolf Therapeutics from $8.00 to $6.00 and set an "outperform" rating on the stock in a research note on Friday, May 9th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Werewolf Therapeutics currently has a consensus rating of "Buy" and an average price target of $8.00.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL traded up $0.04 during trading hours on Monday, hitting $1.32. 114,677 shares of the company traded hands, compared to its average volume of 162,543. The stock has a market capitalization of $60.36 million, a price-to-earnings ratio of -0.80 and a beta of 0.63. Werewolf Therapeutics has a twelve month low of $0.5950 and a twelve month high of $4.18. The firm has a 50-day moving average of $1.23 and a 200 day moving average of $1.14. The company has a current ratio of 5.30, a quick ratio of 8.09 and a debt-to-equity ratio of 0.60.

Institutional Investors Weigh In On Werewolf Therapeutics

Large investors have recently made changes to their positions in the company. Jane Street Group LLC grew its holdings in shares of Werewolf Therapeutics by 261.2% in the 4th quarter. Jane Street Group LLC now owns 54,713 shares of the company's stock worth $81,000 after purchasing an additional 39,564 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in shares of Werewolf Therapeutics in the 1st quarter worth about $34,000. D. E. Shaw & Co. Inc. bought a new stake in shares of Werewolf Therapeutics in the 4th quarter worth about $26,000. Deutsche Bank AG grew its holdings in shares of Werewolf Therapeutics by 450.7% in the 4th quarter. Deutsche Bank AG now owns 101,626 shares of the company's stock worth $150,000 after purchasing an additional 83,172 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Werewolf Therapeutics by 7.3% in the 4th quarter. Northern Trust Corp now owns 244,390 shares of the company's stock worth $362,000 after purchasing an additional 16,640 shares during the last quarter. Institutional investors own 64.84% of the company's stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.